tickerreport.com
Neutralwww.tickerreport.com ·
What Is Hc Wainwrights Estimate for Oncy Fy2030 Earnings
Lung CancerSeigeCheckpointUnrest Checkpoint
Topic context
This topic has been covered 105739 times in the last 7 days across our monitored publishers.
The full article is on the original publisher site.
AI insight
AI-generatedAnalyst estimate revision for a clinical-stage biotech firm; no direct commercial mechanism beyond equity valuation. Weak signal: EPS revision reflects lower expected profitability but no product revenue, supply chain, or regulatory catalyst. Sector PHARMA_BIOTECH is relevant but impact is limited to stock sentiment.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- HC Wainwright revised FY2030 EPS estimate for Oncolytics Biotech from $0.18 to $0.14.
- HC Wainwright maintains 'Buy' rating with $10.00 price target.
- Consensus FY current-year EPS is ($0.20).
- Stock opened at $0.81, market cap $96.71 million.
- Quarterly EPS ($0.08) missed consensus ($0.05).
Related stories
prnewswire.com
Fosun International Recognized on Fortunes 2026 Most Admired Chinese Companies List
prnewswire.com
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
manilatimes.net
Fosun International Recognized on Fortunes 2026 Most Admired Chinese Companies List
theglobeandmail.com
Article Investors Hunt for AI Winners in Small Cap US Tech Stocks
rnz.co.nz